| Literature DB >> 32714086 |
Hiroshi Ohara1,2, Masanori Watanabe1, Masamu Takebayashi1, Saori Abe1, Tetsuya Matsuzaki1, Masataka Hayasaka1.
Abstract
Catheter-related bloodstream infections (CRBSIs) due to pathogenic microorganisms pose a major threat to patients requiring parenteral nutrition (PN). Additives contained in medicines and foods have antiproliferative and bacteriostatic effects on pathogenic microorganisms. Therefore, PN solutions containing additives may also have an antibacterial effect. However, so far, there have been no reports on or observations of a PN solution with bactericidal activity. In this study, we assessed several nutrition solutions with antimicrobial activities and investigated their effects on pathogenic microorganisms colonizing catheter lumens. We selected the highly acidic Plas-Amino® (PA), which contains a large amount of sodium bisulfite as a preservative and potentially has an antimicrobial effect. In this study, we used the following pathogenic bacteria as the main causatives of CRBSIs: Staphylococcus aureus, Staphylococcus epidermidis, Bacillus cereus, Serratia marcescens, Pseudomonas aeruginosa, and Candida albicans. We then created a catheter lumen microorganism contamination model and evaluated the antibacterial effect of PA; we found that all bacteria in the control group grew significantly in the catheter lumen in a time-dependent manner at 48 and 72 h. On the other hand, we demonstrated that PA has bactericidal effects on S. aureus, S. epidermidis, B. cereus, S. marcescens, and P. aeruginosa in the catheter lumen and confirmed that it has a remarkable antiproliferative effect on C. albicans. Hence, we concluded that highly acidic PN solutions that contain a preservative like sodium bisulfite have bactericidal and growth inhibition effects on microorganisms in the catheter lumens of patients with CRBSIs and patients with totally implantable central venous access devices, in whom it is difficult to remove the catheter. © The author(s).Entities:
Keywords: bactericidal action; catheter-related bloodstream infection; microbial growth inhibition; parenteral nutrition; sodium bisulfite
Mesh:
Substances:
Year: 2020 PMID: 32714086 PMCID: PMC7378669 DOI: 10.7150/ijms.48829
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Composition of BFLUID® (BF) and Plas-Amino® (PA)
| Category | Component | BFLUID® | Plas-Amino® |
|---|---|---|---|
| Carbohydrate | Glucose | 37.50 g | 37.50 g |
| Amino Acids | L-Leucine | 2.100 g | 2.05 g |
| L-Isoleucine | 1.200 g | 0.90 g | |
| L-Valine | 1.200 g | 1.00 g | |
| L-Lysine Hydrochloride | 1.965 g | 3.10 g | |
| (as L-Lysine) | (1.573 g) | (2.48 g) | |
| L-Threonine | 0.855 g | 0.90 g | |
| L-Tryptophan | 0.300 g | 0.29 g | |
| L-Methionine | 0.585 g | 1.20 g | |
| Acetylcysteine | 0.202 g | - | |
| (as L-Cysteine) | (0.150 g) | - | |
| L-Phenylalanine | 1.050 g | 1.45 g | |
| L-Tyrosine | 0.075 g | - | |
| L-Arginine | 1.575 g | 1.10 g | |
| L-Histidine | 0.750 g | 0.50 g | |
| L-Alanine | 1.200 g | - | |
| L-Proline | 0.750 g | - | |
| L-Serine | 0.450 g | - | |
| Glycine | 0.855 g | 1.70 g | |
| L-Aspartic Acid | 0.150 g | - | |
| L-Glutamic Acid | 0.150 g | - | |
| Electrolytes | Na+ | 17.5 mEq | 17 mEq |
| K+ | 10 mEq | - | |
| Mg2+ | 2.5 mEq | - | |
| Ca2+ | 2.5 mEq | - | |
| Cl- | 17.5 mEq | 17 mEq | |
| SO42- | 2.5 mEq | - | |
| Acetate- | 8 mEq | - | |
| L-Lactate- | 10 mEq | - | |
| Citrate3- | 3 mEq | - | |
| P | 5 mmol | - | |
| Zn | 2.5 μmol | - | |
| Vitamin | Thiamine Chloride Hydrochloride | 0.96 mg | - |
| Approximately 6.7 | Approximately 4.6 | ||
| Approximately 3 | Approximately 3 | ||
| Sodium Bisulfite | 0.05 g/L | 0.5 g/L | |
ORP: osmotic pressure ratio to physiological saline.
Composition of MVs (Otsuka MV Injection®)
| Composition per 4 mL | |
|---|---|
| Vitamin B1 | 3.1 mg |
| Vitamin B2 | 3.6 mg |
| Vitamin B6 | 4.0 mg |
| Vitamin B12 | 0.005 mg |
| Vitamin C | 100 mg |
| Folic Acid | 0.4 mg |
| Nicotinamide | 40 mg |
| Biotin | 0.06 mg |
| Panthenol | 14 mg |
| Vitamin A Oil | 3300 Vit.A IU |
| Vitamin D3 | 0.005 mg |
| Vitamin E | 10 mg |
| Vitamin K | 2 mg |
Vit.A IU, international unit for vitamin A.
Figure 1Experimental procedure, first experiment for all bacterial pathogens. In the control group, BFLUID® (BF) with Otsuka MV Injection® (MVs, BF-MVs) was added dropwise for 72 h. In the test group, BF-MVs was added dropwise for 24 h, and then Plas-Amino® (PA) was added dropwise for 18 h, followed by the addition of BF-MVs dropwise again for 30 h. Then, after 24, 48, and 72 h, all aliquot samples were collected and the colony-forming unit (CFU)/mL value was measured.
Figure 2Bactericidal and antiproliferative effects of Plas-Amino® (PA) on pathogenic microorganisms. Droplet samples were collected at 24, 48, and 72 h, and the colony-forming unit (CFU)/mL value was measured. (A) Bactericidal effect of PA on Staphylococcus aureus. (B) Bactericidal effect of PA on Staphylococcus epidermidis. (C) Bactericidal effect of PA on Bacillus cereus. (D) Bactericidal effect of PA on Serratia marcescens. (E) Bactericidal effect of PA on Pseudomonas aeruginosa. (F) Antiproliferative effect of PA on Candida albicans. PA (◆) and BFLUID® (BF) with multivitamins (BF-MVs; ■) were used as the control. All data are represented as the mean ± standard deviation (SD; n=3). n.d.: not detectable.